A Pharmacokinetic Study of Valacyclovir in Pediatric Oncology Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2001-08-31

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research is to study the pharmacology (how the body handles this drug) of valacyclovir in children receiving treatment for cancer. This study will last approximately 7 days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Palatability Testing of a New Paediatric Formulation of Valacyclovir

NCT01682109

Varicella Zoster Virus Infection Herpes Simplex Virus Infection

COMPLETED PHASE4

Pharmacokinetics of Valacyclovir Oral Solution in Children

NCT04081480

Herpes Simplex Virus Infection Varicella Zoster Virus Infection

TERMINATED NA

Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir

NCT01689285

Varicella Zoster Virus Infection Herpes Simplex Virus Infection

COMPLETED PHASE1

Valacyclovir in Neonatal Herpes Simplex Virus Disease

NCT04448392

Neonatal Herpes Simplex Infection

COMPLETED PHASE1

A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children

NCT00297206

Herpes Simplex

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, patients will receive a single dose of oral valacyclovir. Blood samples will be drawn to evaluate the pharmacology (how the body handles the drug). Blood samples (less than one teaspoon each) will be obtained before receiving the drug and at 0.5, 1, 1.5, 2, 5, 6, and 8 hours after receiving the drug. The total amount of blood drawn from patients for all blood work including routine blood tests as well as pharmacokinetics will not be greater than 5% of the total blood volume.

We will also have all urine output collected for 8 hours starting at the time patients receive the dose of valacyclovir. A 5cc sample of urine will be collected and analyzed to determine how the body handles the drug at hours 2, 4, 6, and 8.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Valacyclovir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: Patients must be \> / = 2 and \< / = 18 years old.
* Life Expectancy: Patients must have a life expectancy of \> 8 weeks
* Subjects must have a diagnosed malignancy, and must currently be receiving consolidation or maintenance chemotherapy
* Hepatic/Renal Function: Patients must have adequate hepatic function (bilirubin \< / = 1.5 mg/dl: SGPT \< 3x normal) and adequate renal function (creatinine \< / = 1 mg/dl: BUN \< 20 )
* Medication Tolerance: Patients must be able to swallow pills or tolerate a suspension of the medication
* Fluid Tolerance: Children must be able to retain liquids at the time of enrollment
* Informed Consent: Written informed consent will be obtained from all patients and/or their parents prior to enrollment
* Pregnancy: Women of childbearing age must have a negative serum pregnancy test at the time of study entry

Exclusion Criteria

* More than one prior chemotherapy regimen.
* Patients with uncontrolled infections.
* Subjects with known history of adverse reaction to acyclovir in the past.
* Patients with concurrent infections requiring treatment with valacyclovir or acyclovir.

Minimum Eligible Age

2 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No